Search | IOVS | ARVO Journals

Showing 1 – 20 of 49

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Survival of uveal melanoma patients with additional malignancies.

Pablo Emiliano Galarza; Jacob Pe'er; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2873. doi:

ARVO Annual Meeting Abstract June 2020

Topical interferon alpha 2a for ocular surface tumors

Jacob Pe'er; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4659. doi:

ARVO Annual Meeting Abstract June 2020

A novel type of corneal epitheliopathy from a new class of antibody-drug conjugate anti-cancer treatments

Shahar Frenkel; ABRAHAM SOLOMON; Jacob Pe'er

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3633. doi:

ARVO Annual Meeting Abstract July 2019

Treatment of vitreo-retinal lymphoma - 20 years of experience

Jacob Pe'er; Zohar Habot-Wilner; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2777. doi:

Perspective January 2019

Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference

PDF

Justine R. Smith; Jacob Pe'er; Rubens N. Belfort; Fatima Cardoso; Richard D. Carvajal; Carlos Carvalho; Sarah E. Coupland; Laurence Desjardins; Jasmine H. Francis; Brenda L. Gallie; Dan S. Gombos; Hans E. Grossniklaus; Steffen Heegaard; Martine J. Jager; Swathi Kaliki; Bruce R. Ksander; Markus Maeurer; Eduardo Moreno; Jose S. Pulido; Bettina Ryll; Arun D. Singh; Junyang Zhao; António Parreira; David J. Wilson; Joan M. O'Brien
TAGS: carcinogenesis, medical oncology, ophthalmology, tumorigenesis, vision research, intraocular melanoma, neoplasms, cancer, eye cancer
Trans. Vis. Sci. Tech.. 2019; 8(1):9. doi: https://doi.org/10.1167/tvst.8.1.9

ARVO Annual Meeting Abstract July 2018

Frequency of atypical vascularization during IAC for retinoblastoma

Jacob Pe'er; Nadav Levinger; Jose Cohen; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1643. doi:

ARVO Annual Meeting Abstract July 2018

Serum exosome analysis as a predictive biomarker for metastatic uveal melanoma

Shahar Frenkel; Shahar Luski; Pratibha Gaur; Jacob Pe'er; Saray Tabak; Elie Beit-Yannai

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3186. doi:

Anatomy and Pathology/Oncology February 2018

Leucine-Rich α-2-Glycoprotein-1 (LRG-1) Expression in Retinoblastoma

PDF

Radgonde Amer; Liran Tiosano; Jacob Pe'er
TAGS: glycoproteins, leucine, retinoblastoma, vascular endothelial growth factor a, neoplasms
Invest. Ophthalmol. Vis. Sci.. 2018; 59(2):685-692. doi: https://doi.org/10.1167/iovs.17-22785

ARVO Annual Meeting Abstract June 2017

Leaky Choroidal Nevi: A Clinical, Imaging and Therapeutic Analysis

Shahar Frenkel; Gustavo A. Gutiérrez-Vargas; Jacob Pe'er

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1787. doi:

ARVO Annual Meeting Abstract June 2017

The Use of Intravitreal Methotrexate for Treating Vitreoretinal Lymphoma

Jacob Pe'er; Ron Kaufman; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1800. doi:

ARVO Annual Meeting Abstract September 2016

The clinical presentation of retinoblastoma patients with mosaics

Shahar Frenkel; Jacob Pe'er

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3672. doi:

ARVO Annual Meeting Abstract September 2016

Brachytherapy with Ru-106 plaques as a primary treatment for retinoblastoma in Israel

Jacob Pe'er; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3679. doi:

ARVO Annual Meeting Abstract September 2016

Drug delivery for ocular surface malignancies

Jacob Pe'er

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract June 2015

Novel combinatorial treatment option for metastatic uveal melanoma

Shahar Frenkel; Dudi Shneor; Alik Honigman; Jacob Pe'er

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4337. doi:

ARVO Annual Meeting Abstract June 2015

Diagnosis of Vitreoretinal Lymphoma: The Use of Cytology, Gene Rearrangement, and IL-10/IL-6 Ratio Jacob Pe'er 1 , Shahar Frenkel 1 , Inna Kalickman 2 , Yoav Sherman 3 , Bela Maly 3 , Dina Ben Yehuda 4 , and Vivian Barak 2 Departments of 1 Ophthalmology, 2 Oncology, 3 Pathology, and 4 Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel .

Jacob Pe'er

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1289. doi:

ARVO Annual Meeting Abstract April 2014

sIL-2R an immuno-biomarker for prediction of metastases in uveal melanoma

Vivian Barak; Jacob Pe'er; Inna Kalickman; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5076. doi:

ARVO Annual Meeting Abstract April 2014

NFkB Inhibition in Uveal Melanoma - construction of a new delivery system

Shahar Frenkel; Dudi Shneor; Alik Honigman; Jacob Pe'er

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):846. doi:

ARVO Annual Meeting Abstract June 2013

Genetic Characterization among 232 Retinoblastoma Patients

Jacob Pe'er; Ofira Zloto; Michael Weintraub; Michal Sagi; Israela Lerer; Avishag Nadel; Ido Rot; Naomi Shoshani; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3976. doi:

ARVO Annual Meeting Abstract June 2013

Targeting Uveal Melanoma Response to Hypoxia

Dudi Shneor; Alik Honigman; Jacob Pe'er; Shahar Frenkel

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4527. doi:

ARVO Annual Meeting Abstract June 2013

NFkB Inhibition in Uveal Melanoma - Contrariety of in vitro vs. in vivo Results

Shahar Frenkel; Dudi Shneor; Jacob Pe'er; Alik Honigman

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4529. doi:

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Survival of uveal melanoma patients with additional malignancies.

Topical interferon alpha 2a for ocular surface tumors

A novel type of corneal epitheliopathy from a new class of antibody-drug conjugate anti-cancer treatments

Treatment of vitreo-retinal lymphoma - 20 years of experience

Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference

Frequency of atypical vascularization during IAC for retinoblastoma

Serum exosome analysis as a predictive biomarker for metastatic uveal melanoma

Leucine-Rich α-2-Glycoprotein-1 (LRG-1) Expression in Retinoblastoma

Leaky Choroidal Nevi: A Clinical, Imaging and Therapeutic Analysis

The Use of Intravitreal Methotrexate for Treating Vitreoretinal Lymphoma

The clinical presentation of retinoblastoma patients with mosaics

Brachytherapy with Ru-106 plaques as a primary treatment for retinoblastoma in Israel

Drug delivery for ocular surface malignancies

Novel combinatorial treatment option for metastatic uveal melanoma

sIL-2R an immuno-biomarker for prediction of metastases in uveal melanoma

NFkB Inhibition in Uveal Melanoma - construction of a new delivery system

Genetic Characterization among 232 Retinoblastoma Patients

Targeting Uveal Melanoma Response to Hypoxia

NFkB Inhibition in Uveal Melanoma - Contrariety of in vitro vs. in vivo Results

To View More...

You must be signed into an individual account to use this feature.